** Shares of Organovo Holdings ONVO.O more than tripled to $1.35 premarket
** ONVO says it is selling its FXR program, including lead asset FXR314, to Eli Lilly LLY.N
** ONVO's FXR program is focused on developing novel treatment approaches for inflammatory bowel disease
** LLY will pay ONVO $10 mln upfront and $50 mln if certain milestones are met in future, according to agreement
** LLY is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development
** Acquisition will allow Eli Lilly to further develop FXR314, starting from mid-stage, ONVO says
** ONVO fell ~68% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。